1016266-41-3Relevant academic research and scientific papers
The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor
Bailey, James M.,Scott, Jackie S.,Basilla, Jonathan B.,Bolton, Victoria J.,Boyfield, Izzy,Evans, David G.,Fleury, Etienne,Heightman, Tom D.,Jarvie, Emma M.,Lawless, Kirk,Matthews, Kim L.,McKay, Fiona,Mok, Hindy,Muir, Alison,Orlek, Barry S.,Sanger, Gareth J.,Stemp, Geoffrey,Stevens, Alexander J.,Thompson, Mervyn,Ward, John,Vaidya, Kalindi,Westaway, Susan M.
scheme or table, p. 6452 - 6458 (2010/05/02)
Optimisation of a series of benzazepine sulfonamide hit compounds identified from high throughput screening led to the discovery of a new series of tractable, potent motilin receptor agonists.
USE OF ION CHANNEL MODULATORS IN THE PROPHYLAXIS AND TREATMENT OF INFLAMMATORY AND IMMUNOLOGICAL DISEASES
-
Page/Page column 47-48, (2010/11/30)
Use of compounds of general formula (1) and pharmacologically acceptable salts and prodrugs thereof:Formula (1) wherein A and B are CH2 or CH2CH2, R1 is hydrogen, alkyl, cycloalkyl, aryl, aralkyl or heteroaralkyl, R2, R3 and R4 are selected from hydrogen, alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl or cyano; X is R5CO, R5SO2, R5R7NCO, R5R7NSO2, R5SO2NR7CO or CO2R8, Y is R6CO, R6SO2, R6R7NCO, R6R7NSO2, R6SO2NR7CO or CO2R8, R5 and R6 are hydrogen, alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, R7 is hydrogen, alkyl, aryl or aralkyl, and R8 is alkyl, aryl, aralkyl, alkoxyalkyl, heteroaryl or heteroarylalkyl, provided that when X is R5CO or R5SO2, then Y is not R6CO, R6SO2 or R6R7NCO, in the manufacture of a medicament for the prophylaxis or treatment of inflammatory or immunological disease.
